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Purpose of the study
Starting HAART at low CD4 counts may be associated
with impaired CD4 recovery. However, the factors associ-
ated with late presentation and delay of HAART may con-
found any associations with CD4 response. We studied
CD4, VL and clinical outcomes over 4 years of HAART in
subjects from the UK CHIC Study who maintained VL
suppression for the first year on HAART, stratified by pre-
HAART CD4.
Methods
We identified ARV-naïve adults starting HAART from
1998–2006 (NRTI+NNRTI or PI/r) with pre-HAART CD4
<350 cells and VL >500 cp/ml. Patients were excluded if
they had <1 year follow-up, they did not suppress VL, they
experienced VL rebound in the first year, or they stopped
HAART. CD4 rises were compared using Kruskal-Wallis
tests in those starting with pre-HAART CD4 of <100
(group 1), 101–200 (group 2) or >200 (group 3) cells; VL
rebound (>1000 cp/ml) and progression to new AIDS/
death were compared using Kaplan-Meier analysis.
Summary of results
3,491 of 6,904 ARV-naïve adults starting HAART were eli-
gible. Most were male (74%), white (56%), MSM (54%)
with a median age of 36 years. Median follow-up was 3.6
(range 1, 9) years after HAART. 1,116 (32.0%), 1,186
(34.0%) and 1,189 (34.1%) were in groups 1, 2 and 3,
respectively. 3,029 (87%) started an NNRTI (mainly EFV)
and 13% a PI/r-based regimen (mainly LPV). Whilst the
median CD4 count was significantly lower in group 1 in
all 4 years, the median CD4 increase from pre-HAART was
significantly higher in group 1 than in groups 2/3 after 2,
3 and 4 years (median CD4 increases at year 4 of 345, 320
and 333 cells in groups 1, 2 & 3). The cumulative risk of
VL rebound at years 2, 3 and 4 was 6.9, 11.9 and 15.5%,
with no significant difference across groups (p = 0.10, log-
rank test). Group 1 had higher rates of clinical progression
than group 3 at 2 years (1.8% vs. 0.8%); this effect per-
sisted over the next 2 years (RHs of 2.10, 1.75 and 2.23 in
years 2, 3 and 4). Whereas group 2 had a higher rate of
clinical progression than group 3 in year 2 after HAART
(1.4% vs. 1.8%), this effect weakened (RHs of 1.76, 1.21
and 0.93 in years 2, 3 and 4).
Conclusion
Individuals starting HAART at CD4 counts ≤100 cells who
maintain VL suppression for a year have lower median
CD4 counts by 4 years after HAART. However, CD4
increases in this group are greater than those in patients
starting at higher CD4s, suggesting that any disadvantage
may be lost over time if patients can maintain VL suppres-
sion.
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